Efficacy of neoadjuvant atezolizumab treatment in patients with advanced urothelial bladder cancer according to the BASQ classification: a study protocol for an open-label, two-cohort, phase II trial
Sign Up to like & getrecommendations! Published in 2020 at "BMJ Open"
DOI: 10.1136/bmjopen-2019-035530
Abstract: Introduction Atezolizumab is a programmed death ligand-1 inhibitor for urothelial bladder cancer treatment. Atezolizumab has become the standard therapy for patients with urothelial bladder cancer who are not responding to cisplatin-based chemotherapy and is also… read more here.
Keywords: bladder cancer; trial; neoadjuvant atezolizumab; treatment ... See more keywords
MHCI and FOXP3 predicting outcome to neoadjuvant atezolizumab in sequential urothelial cancer tissue.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.6_suppl.541
Abstract: 541Background: Biomarker analysis predicting outcome with neoadjuvant atezolizumab in muscle invasive bladder cancer (MIBC) was performed. This includes previously unreported findings with FOXP3 an... read more here.
Keywords: predicting outcome; outcome neoadjuvant; neoadjuvant atezolizumab; mhci foxp3 ... See more keywords